Clinical Trials Sponsored by Taro Pharmaceuticals USA

Total 483 results

Taro Pharmaceuticals USA

Completed

Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis

Plaque Psoriasis

United States
Taro Pharmaceuticals USA

Completed

A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
Taro Pharmaceuticals USA

Completed

A Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
Taro Pharmaceuticals USA

Completed

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
Taro Pharmaceuticals USA

Completed

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.

Atopic Dermatitis

United States
Taro Pharmaceuticals USA

Completed

Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis

Scalp Psoriasis
Taro Pharmaceuticals USA

Completed

A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study

Plaque Psoriasis
Taro Pharmaceuticals USA

Completed

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression

Plaque Psoriasis

United States
Taro Pharmaceuticals USA

Completed

Efficacy Study in Patients With Acne Vulgaris.

Acne Vulgaris
Taro Pharmaceuticals USA

Completed

Safety and Efficacy of NVXT Solution in Mild-to-Moderate Fungal Infection of the Toe Nail

Onychomycosis
Taro Pharmaceuticals USA

Completed

Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis

Tinea Pedis
Taro Pharmaceuticals USA

Completed

To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
Taro Pharmaceuticals USA

Completed

Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya® Gel and Both to a Vehicle Control in the Treatment of Acne Vulgaris

Acne Vulgaris
Taro Pharmaceuticals USA

Completed

Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Acne Vulgaris
Taro Pharmaceuticals USA

Completed

Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris

Acne Vulgaris
Taro Pharmaceuticals USA

Completed

Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo® and Both to a Placebo Control in the Treatment of Acne Vulgaris

Acne Vulgaris
Taro Pharmaceuticals USA

Completed

Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice

Pediculosis

United States
Taro Pharmaceuticals USA

Completed

Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis

Psoriasis

United States
Taro Pharmaceuticals USA

Completed

Bioequivalence Study of Two Imiquimod Cream 5%

Actinic Keratosis

United States
Taro Pharmaceuticals USA

Completed

Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.

Actinic Keratosis
Taro Pharmaceuticals USA

Completed

A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris

Acne Vulgaris
Taro Pharmaceuticals USA

Completed

A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.

Tinea Versicolor

United States
Taro Pharmaceuticals USA

Completed

A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.

Plaque Psoriasis

United States
Taro Pharmaceuticals USA

Completed

A Study Comparing Oxymetazoline 1% Cream to RHOFADE

Bioequivalence

United States
Taro Pharmaceuticals USA

Completed

A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.

Tinea Pedis

United States
Taro Pharmaceuticals USA

Completed

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
Taro Pharmaceuticals USA

Completed

A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions.

Secondarily Infected Traumatic Skin Lesions
Taro Pharmaceuticals USA

Completed

Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis

Plaque Psoriasis

United States
Taro Pharmaceuticals USA

Completed

Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product

Scalp Psoriasis

United States
Taro Pharmaceuticals USA

Completed

Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS

Psoriasis

United States
Taro Pharmaceuticals USA

Completed

A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%

Lice; Head Lice

United States
Taro Pharmaceuticals USA

Completed

Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis

Tinea Pedis
Taro Pharmaceuticals USA

Completed

A Study Comparing Tazarotene Cream 0.1% to Tazorac® and Both to a Placebo Control in the Treatment of Acne Vulgaris

Acne Vulgaris
Taro Pharmaceuticals USA

Completed

Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Acne Vulgaris
Taro Pharmaceuticals USA

Completed

Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis

Tinea Pedis

United States, Belize
Taro Pharmaceuticals USA

Completed

A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis

Tinea Pedis
Taro Pharmaceuticals USA

Completed

Pharmacokinetics of Malathion Gel 0.5% and Malathion 0.5% Lotion (Ovide) in Patients With Head Lice

Pediculosis

India
Taro Pharmaceuticals USA

Completed

A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea (MTZG)

Rosacea

United States
Taro Pharmaceuticals USA

Terminated

Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice

Lice Infestations

United States
Taro Pharmaceuticals USA

Completed

To Evaluate the Therapeutic Equivalence and Safety of Azelaic Acid 15% Topical Gel

Rosacea
Taro Pharmaceuticals USA

Completed

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
Taro Pharmaceuticals USA

Completed

An Open-Label Study to Assess Safety

Plaque Psoriasis

United States
Taro Pharmaceuticals USA

Completed

A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
Taro Pharmaceuticals USA

Completed

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis

Scalp Psoriasis

United States
Taro Pharmaceuticals USA

Completed

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea

Rosacea

United States
Taro Pharmaceuticals USA

Completed

Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study

Onychomycosis

United States
Taro Pharmaceuticals USA

Completed

Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis

Atopic Dermatitis

United States
Taro Pharmaceuticals USA

Completed

Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis

Dermatitis, Atopic

United States
Taro Pharmaceuticals USA

Completed

Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis

Plaque Psoriasis

United States
Taro Pharmaceuticals USA

Completed

Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis

Scalp Psoriasis

United States

3

Subscribe